STADA Arzneimittel AG Report issue

For profit Phase 2 Phase 3
Founded: Bad Vilbel Germany (1895)
Status: No NME R&D (1895)

Organization Overview

First Clinical Trial
2012
NCT01714414
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Pharmaceutical Company (STADA Vietnam Joint Venture Co. Ltd.) | Stada Arzneimittel AG | STADA Vietnam Joint Venture Co. Ltd

Active Ingredients

Drugs in Phase 3 Trials (1)

ranibizumab (lucentis) (1 trial)

Drugs in Phase 2 Trials (4)

efavirenz (sustiva) (1 trial)

fozivudine tidoxil (1 trial)

lamivudine (epivir) (1 trial)

zidovudine (retrovir) (1 trial)

Drugs in Other Trials (1)

Key: STADA Arzneimittel AG (0) Acquired (1)

nevulose (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Macular Degeneration (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 6